SomaCode: GPS for Cell Therapy
Among the largest unsolved challenges in cell therapy is the need to efficiently deliver therapeutic cells to specific tissue locations in the body so they can interact directly with diseased cells.
SomaCode is a platform technology and discovery pipeline that uses high-throughput, in vivo pooled genetic screens to identify unique molecular signatures of disease and engineer therapeutic cells that home to that signature. SomaCode aims to identify collections of genetic modifications that reliably guide a therapeutic cell to its disease target.
Crucially, these experiments are performed in vivo in mice, ensuring that the tested cells experience physiological conditions closer to what they would encounter in a living human body.
SomaCode currently uses primary T cells, but could be used with any cell type with therapeutic potential.
SomaCode was conceived in the lab of Wyss Core Faculty member George Church, Ph.D., whose members pride themselves on tackling big, complex problems in biological engineering. The project is led by Soufiane Aboulhouda and Oliver Dodd, both graduate students in the lab, and is advised by David Thompson, Ph.D., a Staff Scientist and member of the Advanced Technology Team at the Wyss Institute.
https://wyss.harvard.edu/technology/somacode-getting-cell-therapies-where-they-need-to-go/
ارسال به دوستان